vs
Orthofix Medical Inc.（OFIX）与RENASANT CORP（RNST）财务数据对比。点击上方公司名可切换其他公司
RENASANT CORP的季度营收约是Orthofix Medical Inc.的1.2倍（$273.8M vs $219.9M），RENASANT CORP净利率更高（32.2% vs -1.0%，领先33.2%），过去两年RENASANT CORP的营收复合增速更高（29.3% vs 8.0%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
瑞耐桑特银行是美国密西西比州图珀洛的区域商业金融机构，母公司为瑞耐桑特公司，在阿拉巴马、佛罗里达、佐治亚、密西西比、路易斯安那、田纳西、北卡罗来纳、南卡罗来纳八州拥有280多家分支机构，旗下还运营内容平台“瑞耐桑特国度”，发布博客及节目内容。
OFIX vs RNST — 直观对比
营收规模更大
RNST
是对方的1.2倍
$219.9M
净利率更高
RNST
高出33.2%
-1.0%
两年增速更快
RNST
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $273.8M |
| 净利润 | $-2.2M | $88.2M |
| 毛利率 | 71.1% | — |
| 营业利润率 | 0.2% | — |
| 净利率 | -1.0% | 32.2% |
| 营收同比 | 2.0% | — |
| 净利润同比 | 92.4% | 112.5% |
| 每股收益（稀释后） | $-0.05 | $0.94 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXRNST
| Q1 26 | — | $273.8M | ||
| Q4 25 | $219.9M | $278.4M | ||
| Q3 25 | $205.6M | $269.5M | ||
| Q2 25 | $203.1M | $267.2M | ||
| Q1 25 | $193.6M | $170.7M | ||
| Q4 24 | $215.7M | $167.1M | ||
| Q3 24 | $196.6M | $220.3M | ||
| Q2 24 | $198.6M | $163.8M |
净利润OFIXRNST
| Q1 26 | — | $88.2M | ||
| Q4 25 | $-2.2M | $78.9M | ||
| Q3 25 | $-22.8M | $59.8M | ||
| Q2 25 | $-14.1M | $1.0M | ||
| Q1 25 | $-53.1M | $41.5M | ||
| Q4 24 | $-29.1M | $44.7M | ||
| Q3 24 | $-27.4M | $72.5M | ||
| Q2 24 | $-33.4M | $38.8M |
毛利率OFIXRNST
| Q1 26 | — | — | ||
| Q4 25 | 71.1% | — | ||
| Q3 25 | 72.2% | — | ||
| Q2 25 | 68.7% | — | ||
| Q1 25 | 62.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 68.7% | — | ||
| Q2 24 | 67.8% | — |
营业利润率OFIXRNST
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | 34.8% | ||
| Q3 25 | -8.3% | 27.9% | ||
| Q2 25 | -7.9% | 1.0% | ||
| Q1 25 | -25.2% | 30.4% | ||
| Q4 24 | -5.3% | 29.8% | ||
| Q3 24 | -9.6% | 44.2% | ||
| Q2 24 | -12.5% | 29.6% |
净利率OFIXRNST
| Q1 26 | — | 32.2% | ||
| Q4 25 | -1.0% | 28.4% | ||
| Q3 25 | -11.1% | 22.2% | ||
| Q2 25 | -6.9% | 0.4% | ||
| Q1 25 | -27.4% | 24.3% | ||
| Q4 24 | -13.5% | 26.8% | ||
| Q3 24 | -13.9% | 32.9% | ||
| Q2 24 | -16.8% | 23.7% |
每股收益（稀释后）OFIXRNST
| Q1 26 | — | $0.94 | ||
| Q4 25 | $-0.05 | $0.78 | ||
| Q3 25 | $-0.57 | $0.63 | ||
| Q2 25 | $-0.36 | $0.01 | ||
| Q1 25 | $-1.35 | $0.65 | ||
| Q4 24 | $-0.76 | $0.70 | ||
| Q3 24 | $-0.71 | $1.18 | ||
| Q2 24 | $-0.88 | $0.69 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $1.2B |
| 总债务越低越好 | — | $806.2M |
| 股东权益账面价值 | $450.0M | $3.9B |
| 总资产 | $850.6M | $27.1B |
| 负债/权益比越低杠杆越低 | — | 0.21× |
8季度趋势，按日历期对齐
现金及短期投资OFIXRNST
| Q1 26 | — | $1.2B | ||
| Q4 25 | $82.0M | $1.1B | ||
| Q3 25 | $62.9M | $1.1B | ||
| Q2 25 | $65.6M | $1.4B | ||
| Q1 25 | $58.0M | $1.1B | ||
| Q4 24 | $83.2M | $1.1B | ||
| Q3 24 | $30.1M | $1.3B | ||
| Q2 24 | $26.4M | $851.9M |
总债务OFIXRNST
| Q1 26 | — | $806.2M | ||
| Q4 25 | — | $499.8M | ||
| Q3 25 | $157.2M | $558.9M | ||
| Q2 25 | $157.0M | $557.0M | ||
| Q1 25 | $156.9M | $433.3M | ||
| Q4 24 | $157.0M | $430.6M | ||
| Q3 24 | $118.5M | $433.2M | ||
| Q2 24 | $118.0M | $428.7M |
股东权益OFIXRNST
| Q1 26 | — | $3.9B | ||
| Q4 25 | $450.0M | $3.9B | ||
| Q3 25 | $442.5M | $3.8B | ||
| Q2 25 | $458.3M | $3.8B | ||
| Q1 25 | $458.3M | $2.7B | ||
| Q4 24 | $503.1M | $2.7B | ||
| Q3 24 | $525.9M | $2.7B | ||
| Q2 24 | $546.0M | $2.4B |
总资产OFIXRNST
| Q1 26 | — | $27.1B | ||
| Q4 25 | $850.6M | $26.8B | ||
| Q3 25 | $832.6M | $26.7B | ||
| Q2 25 | $837.2M | $26.6B | ||
| Q1 25 | $823.1M | $18.3B | ||
| Q4 24 | $893.3M | $18.0B | ||
| Q3 24 | $867.9M | $18.0B | ||
| Q2 24 | $882.0M | $17.5B |
负债/权益比OFIXRNST
| Q1 26 | — | 0.21× | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | 0.36× | 0.15× | ||
| Q2 25 | 0.34× | 0.15× | ||
| Q1 25 | 0.34× | 0.16× | ||
| Q4 24 | 0.31× | 0.16× | ||
| Q3 24 | 0.23× | 0.16× | ||
| Q2 24 | 0.22× | 0.18× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | — |
| 自由现金流经营现金流 - 资本支出 | $16.8M | — |
| 自由现金流率自由现金流/营收 | 7.6% | — |
| 资本支出强度资本支出/营收 | 4.9% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-1.3M | — |
8季度趋势，按日历期对齐
经营现金流OFIXRNST
| Q1 26 | — | — | ||
| Q4 25 | $27.7M | $271.5M | ||
| Q3 25 | $12.4M | $135.5M | ||
| Q2 25 | $11.6M | $-77.3M | ||
| Q1 25 | $-18.4M | $106.2M | ||
| Q4 24 | $23.7M | $106.4M | ||
| Q3 24 | $11.7M | $-1.7M | ||
| Q2 24 | $9.0M | $-49.1M |
自由现金流OFIXRNST
| Q1 26 | — | — | ||
| Q4 25 | $16.8M | $237.8M | ||
| Q3 25 | $2.5M | $120.1M | ||
| Q2 25 | $4.5M | $-87.5M | ||
| Q1 25 | $-25.1M | $101.3M | ||
| Q4 24 | $15.2M | $92.8M | ||
| Q3 24 | $6.3M | $-5.3M | ||
| Q2 24 | $-360.0K | $-52.6M |
自由现金流率OFIXRNST
| Q1 26 | — | — | ||
| Q4 25 | 7.6% | 85.4% | ||
| Q3 25 | 1.2% | 44.6% | ||
| Q2 25 | 2.2% | -32.7% | ||
| Q1 25 | -13.0% | 59.4% | ||
| Q4 24 | 7.0% | 55.5% | ||
| Q3 24 | 3.2% | -2.4% | ||
| Q2 24 | -0.2% | -32.1% |
资本支出强度OFIXRNST
| Q1 26 | — | — | ||
| Q4 25 | 4.9% | 12.1% | ||
| Q3 25 | 4.8% | 5.7% | ||
| Q2 25 | 3.5% | 3.8% | ||
| Q1 25 | 3.5% | 2.8% | ||
| Q4 24 | 4.0% | 8.2% | ||
| Q3 24 | 2.7% | 1.6% | ||
| Q2 24 | 4.7% | 2.1% |
现金转化率OFIXRNST
| Q1 26 | — | — | ||
| Q4 25 | — | 3.44× | ||
| Q3 25 | — | 2.27× | ||
| Q2 25 | — | -75.92× | ||
| Q1 25 | — | 2.56× | ||
| Q4 24 | — | 2.38× | ||
| Q3 24 | — | -0.02× | ||
| Q2 24 | — | -1.26× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
RNST
| Net Interest Income | $223.6M | 82% |
| Noninterest Income | $50.3M | 18% |
